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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the evidence on the effectiveness of different pharmacological interventions used for pain in CYP with LLC.
B A C K G R O U N D
Description of the condition
Pain is one of the most common symptoms in children and young
people (CYP) with life-limiting conditions (LLCs) (Beretta 2010;
Bradshaw 2005; Feudtner 2011; Goldman 2006; Hechler 2008;
Jalmsell 2006; Wolfe 2000). In this review, LLC refers to ‘any
condition from which there is no reasonable hope of cure and
from which the child or young adult will die prematurely’ and
life-threatening conditions are defined as ‘those for which curative
treatment may be feasible but can fail’ (ACT 2009). LLCs are
seen to be rising in the UK (Fraser 2012), with 32 per 10,000
children having an LLC. Sources of pain in this population include
on-going tissue damage due to pathological processes, recurrent
injury, therapy and invasive diagnostic or therapeutic procedures.
Increasing evidence suggests that pain is not well managed in such
children, especially towards the endof life. In a large cross-sectional
study of children with cancer deemed ‘palliative’, Goldman 2006
found that 91.5% of the 164 children in the study experienced
pain in themonth before death. Beretta 2010 found pain to be the
most frequent symptom, with 87% of their sample of 47 children
with cancer experiencing pain during the ‘end stage’. Drake 2003
found that in a sample of 30, 53% of ‘dying’ children experienced
pain in the last week of their lives.
Types of pain
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Pain can be characterised in several ways, individually or in com-
bination: by mechanism or pathophysiology, by intensity, by tem-
porality, or by location.
1. Pain mechanisms
Two basic pain mechanisms are known: nociceptive and neuro-
pathic. Nociceptive pain occurs as the result of tissue damage and/
or inflammation due to physical, chemical or thermal injury (e.g.
traumatic or ischaemic pain, arthritis, muscle spasm, mucositis,
gastritis, or other visceral inflammatory processes). Neuropathic
pain occurs when a lesion of the central or peripheral nervous sys-
tem causes nociceptive dysfunction (IASP 2012) (e.g. from direct
tumour invasion or neural toxicity from chemotherapy or infec-
tion). Nociceptive and neuropathic pain can occur separately or
together in the same individual. The importance of distinguishing
between these two mechanisms is that analgesics are developed for
action on specific mechanisms, and so outcome can vary depend-
ing on the type of pain.
2. Intensity
Pain intensity is usually measured on a scale of 0 to 10, or 0
to 100, using a linear visual analogue scale (VAS) or other pain
intensity ‘measurement tool’ such as the Wong-Baker Faces Scale
(Wong 1988). Intensity can also be described using the four-point
categorical pain intensity scalewith correspondingwording, ’none,
mild, moderate, severe’, or as characterised in the World Health
Organisation (WHO) two-step painmanagement algorithm:mild
VAS (4 to 6),moderate (VAS 7 to 8) or severe (VAS 9 to 10), which
recommends pharmacological interventions of increasing potency
to be used formild andmoderate to severe pain (WHO2012). The
current version of the WHO document differs from the original
three-step ladder, which previously included amiddle step of using
a ‘weaker’ opioid formoderate pain before a ‘stronger’ opioid in the
third step (WHO1996). Pain intensitymeasurement is potentially
complex in children who are too young/preverbal or non-verbal
and unable to describe or quantify their pain. The literature on
this subject is enormous, and a large number of pain measurement
tools suitable for children of different ages in a variety of settings
have been devised (Stinson 2006; Von Baeyer 2009). However, no
definitive tools adequatelymeasure persistent pain in childrenwith
palliative care needs. It is important to recognise that in clinical
studies, the accuracy and reliability of such tools depend on their
validity for use in the situation described (see also Secondary
outcomes).
3. Temporality
Pain can be described by its temporality, although as is emphasised
in the WHO guidelines, temporality does not define treatment
strategies. Pain may be experienced and described as acute pain (<
30 days), chronic pain (> 3 months, with behaviours in response
to pain that do not remit; Hain 2011), persistent pain (covers
‘long-term pain related to medical illness’), episodic or recurrent
pain (‘occurs intermittently over a long period of time and the
child can be pain free in between each painful episode’), break-
through pain (‘temporary increase in the severity of pain over and
above the pre-existing baseline pain level’ and can be predictable or
unpredictable with/without an identifiable cause), incident pain
(from an identifiable cause) and ‘end of dose’ pain (occurs before a
scheduled dose of an around-the-clock analgesic) (WHO 2012).
4. Location
Pain is sometimes characterised by location in the body (e.g. bone
pain, headache, abdominal pain or musculoskeletal pain).
Description of the intervention
For the purpose of this review, we will focus on pharmacological
interventions for the relief of pain causally related to the LLC (dis-
ease-related pain). Pain due to diagnostic and therapeutic proce-
dures and postoperative pain will be excluded.
We shall assess evidence on the effectiveness of pharmacological
interventions, using a framework adapted from WHO guidelines
for pain management in children with medical conditions (WHO
2012). These include the following:
1. Non-opioid analgesics such as paracetamol and non-steroidal
anti-inflammatory drugs (NSAIDs).
2. Opioids such as morphine, methadone, hydromorphone,
buprenorphine, codeine, fentanyl and oxycodone.
3. Local anaesthetics such as lidocaine, bupivacaine and levo bupi-
vacaine.
4. ‘Adjuvant analgesics’. This group includes all drugs given for
pain whose primary indication is not analgesia (e.g. most drugs
commonly used for neuropathic pain, such as tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs),
serotonin-norepinephrine reuptake inhibitors (SNRIs), anticon-
vulsants such as gabapentin and carbamazepine). Muscle relax-
ants and antispasmodics such as baclofen and hyoscine, steroids,
the adrenergic analgesic clonidine and the N-methyl-D-aspartate
(NMDA) antagonists ketamine and dexmedetomidine are also in-
cluded in this category.
How the intervention might work
Pharmacological interventions used to treat pain in CYP with
LLC are numerous and varied; they work in different and complex
ways, with some mechanisms of action still poorly understood.
Wewill briefly consider themechanisms of action according to the
above groupings, giving examples from each group, recognising
that these interventions may be used for pain from a variety of
causes occurring in a variety of temporalities and in a range of
clinical conditions as defined by the International Classification
of Diseases and Related Health Problems, Tenth Revision (ICD-
10), codes.
1. Non-opioids
Non-opioid analgesics traditionally include paracetamol and the
NSAIDs (e.g. ibuprofen, diclofenac, ketorolac). Some of these
analgesics, such as ketorolac and diclofenac, are still of uncertain
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potency. Paracetamol is an analgesic and antipyretic and is prob-
ably the most popular simple analgesic used in children for pain
of mild to moderate intensity (Anderson 2008). Paracetamol has
numerous putative mechanisms of analgesia, such as inhibiting
prostaglandin synthesis within the CNS (cyclo-oxygenase (COX)-
3, COX-2b), blocking impulse generation within the bradykinin-
sensitive chemoreceptors responsible for the generation of noci-
ceptive impulses and antagonising NMDA (Jacqz-Aigrain 2006).
The recommended oral dosage starts at 20 mg/kg as a single dose,
then 10 to 15 mg/kg every 8 to 12 hours for neonates up to 500
mg; 1 g every 4 to 6 hours for 16- to 18-year-olds (BNF 2012).
NSAIDs are a diverse group of drugs that share similar antipyretic,
analgesic and anti-inflammatory effects but may show different
response characteristics (Jacqz-Aigrain 2006). Ibuprofen, for ex-
ample, is a propionic acid derivative and a non-selective cyclo-
oxygenase inhibitor, and its recommended dosage is from 5 mg
per kilogram for infants aged 1 to 3 months up to 300 to 400 mg
for children 12 to 18 years old, 3 to 4 times daily by mouth (BNF
2012).
2. Opioids
Numerous opioids are used to relieve pain in CYP with LLC, in-
cluding (but not limited to) morphine, codeine, buprenorphine,
fentanyl, methadone and oxycodone. Opioids bind to specific re-
ceptors found principally in the central nervous system and the
gastrointestinal tract. Morphine is widely regarded as the first-line
major opioid in CYP with LLC experiencing severe pain. Mor-
phine acts directly on opioid receptors, and a principal metabolite
morphine-6-glucuronide (M6G) also has analgesic activity. Opi-
oids can cause constipation and itch, as well as serious side effects
such as extreme somnolence and depression of respiration, partic-
ularly when used in excess in opioid-naive individuals and young
infants. Although age-related changes in the pharmacokinetics of
opioids are still not well understood, it is known that most age-
related changes are more apparent in the first year of life (as the
result of pharmacokinetic differences, particularly reduced renal
clearance in the first few months of life), and from then on, the
ability of children to metabolise opioids seems similar to that of
adults (Ballentine 2012). Total body morphine clearance is 80%
of adult values by 6 months of age (Bouwmeester 2004). How-
ever, it has been shown that M6G may have faster renal clear-
ance in children, and therefore children may actually need higher
doses given at smaller intervals than in adults (Mashayekhi 2009).
Data on the use of opioids in children with LLC are still lacking
(Zernikow 2009), and on-going debate requires further study to
provide conclusive evidence.
3. Local anaesthetics
Local anaesthetics are ion channel (Na+) blocking drugs that can
treat and prevent all types of pain by blocking nociceptive path-
ways and suppressing nociceptor excitability. They are normally
given by injection close to nerves peripherally or centrally (in-
trathecal or epidural), but topical preparations, including a low-
dose transdermal patch formulation that is effective for some types
of neuropathic pain, are also available. Local anaesthetics in clin-
ical use include the amides lidocaine, bupivacaine and levo bupi-
vacaine, and the esters benzocaine, tetracaine and chloroprocaine.
4. Adjuvants
Adjuvants of interest in this review are drugs whose primary in-
dication is not for pain but that nevertheless have analgesic prop-
erties. Examples of adjuvants for neuropathic pain include some
anticonvulsants, antidepressants, steroids and the NMDA antag-
onist ketamine. Skeletal muscle relaxants, such as baclofen, and
antispasmodics, such as hyoscine, are sometimes given for pain.
Adjuvants make up a varied group and work in many different
ways. In this review, we will consider only adjuvants that are ex-
plicitly administered for pain relief.
Routes of administration
In CYP, the preferred route, where possible, is oral because it is the
simplest, most effective and least painful (WHO 2012). However,
other routes are frequently necessary because of varying clinical
needs. Examples include buccal, rectal, transdermal, intramuscu-
lar, subcutaneous, intravenous, epidural and intrathecal routes.
Why it is important to do this review
The evidence base that is currently available to guide clinical prac-
tice in this area of pain management in CYP with LLC is limited,
and whilst some clinical reviews have been published, no system-
atic review of the international literature has been performed to
date. A recent survey conducted by the Association for Paediatric
Palliative Medicine (APPM) found that clinicians have an urgent
need for systematic review evidence to support their prescribing
(Brook 2012).
O B J E C T I V E S
To evaluate the evidence on the effectiveness of different pharma-
cological interventions used for pain in CYP with LLC.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) (including
cluster RCTs and cross-over trials), quasi-randomised studies, n
of 1 studies, studies that are not randomised but include a clearly
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defined comparator group and time series analyses that have inves-
tigated pharmacological treatments for pain associated with LLC
in CYP.
Types of participants
CYP aged 0 to 18 years (under the age of 19), of either sex, with
an LLC. When screening the papers, the review authors (EB, JL,
HR) will determine whether a condition is life-limiting by us-
ing the Richard Hain Dictionary (Hain 2010) of ICD-10 diag-
noses that have been judged by professionals working in paediatric
palliative care to be life-limiting, and that were recently used in
a paper plotting the national prevalence of LLC in this popula-
tion (Fraser 2012). They can be broken down into the following
groups: infections; leukaemia; other malignant neoplasms; other
neoplasms; sickle cell disorders; thalassaemia and other anaemias;
other diseases of blood and blood-forming organs; cystic fibro-
sis; other endocrine, nutritional and metabolic disorders; epilepsy;
cerebral palsy and other paralytic syndromes; other disorders of
the nervous system; diseases of the circulatory system; diseases of
the respiratory system; diseases of the musculoskeletal system and
connective tissue; diseases of the genitourinary system; conditions
originating in the perinatal period; congenital anomalies and other
causes; and non-malignant haematological disorders (Cochrane
2007). CYP who have pain related to their LLC will be included.
Setting: all settings, including home, hospital, hospice and resi-
dential school.
Types of interventions
Interventions will include any pharmacological intervention given
at any dose for any time period on its own or in combination, or
with a control or comparator group (see below). We will exclude
studies on non-pharmacological interventions.
Control or comparator groups will include any other pharma-
cological interventions; psychological interventions such as relax-
ation, hypnosis and cognitive behavioural therapy; placebo; and
alternative dosing regimens or routes of administration.
Types of outcome measures
For all outcome measures, we will report on the mechanisms of
reporting pain in this population, which commonly features pre-
verbal and non-verbal children, and will take into consideration
in our own results the types of outcome measures used (e.g. ob-
servational/proxy/self-report).
Primary outcomes
Primary outcomes will be pain control and adverse events. Pain
control will be measured by changes in pain intensity scales; other
indicators such as changes in physiological parameters may also
be used (baseline or final value scores at end of follow-up) and
will include both continuous and dichotomous pain outcomes.
We will report what each paper suggests as an adequate reduction
of pain/period of maintenance of pain reduction and will synthe-
sise findings accordingly; however, as advised in the ’Authoring
or Assessing a Cochrane Protocol, Review, or Review Update for
the PaPaS Review Group’ guidance, we will include in our meta-
analysis only studies that use moderate or greater pain as baseline
(Cochrane 2011). To facilitate the review process, all forms of pain
measurement in children, both validated and non-validated, will
be considered during the review process. We shall report data on
all adverse events identified.
Secondary outcomes
As the effectiveness of analgesia is also measured in terms of
changes in physical and psychological functioning and well-being
(McGrath 2008), we will include assessments using validated in-
struments, psychological or social measures such as mental health
status and functioning scales, quality of life, well-being and quality
of care scales for children, such as the Pediatric Quality of Life In-
ventoryT M (PedsQL) (Varni 1999) and European Quality of Life
5-Dimensions (EQ-5D) (Ravens-Sieberer 2010) for their family.
Health service use, including length of stay and number of hospi-
tal admissions, will be reviewed.
Search methods for identification of studies
Wewill use a combination of indexed and free-text terms to reflect
the concepts of ‘pharmacological intervention’, ‘CYP’ and ’pain’.
The LLC element will be identified during screening of papers.
We will modify the search terms according to the constraints of
each database. Please see Appendix 1 for the MEDLINE search
strategy used.
Electronic searches
The following electronic databases will be searched: CENTRAL
(onThe Cochrane Library),MEDLINE, EMBASE, PsycINFO (all
via Ovid SP) and CINAHL (via EBSCO host). No language re-
strictions will be applied.
Searching other resources
We will undertake the following additional search strategies:
1. Conversations with colleagues or key authors, or review of
papers that they recommend
2. Contact with key authors who have published in this field
3. Conference proceedings where available, such as the
International Symposium on Paediatric Pain
4. Internet searches
5. Forward and backward citation searches of included studies
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6. Handsearching of key journals (including Journal of Pain
and Symptom Management)
Data collection and analysis
Selection of studies
Two review authors (EB, JL) will screen abstracts of all identified
studies against the inclusion criteria. A third member of the re-
view team (HR) will screen a sample of the abstracts to further
validate the process. We will retrieve all possibly relevant articles
in full text for assessment against the inclusion criteria. We have
links to researchers with many different languages within Univer-
sity College London (UCL) and so will be able to translate many
non-English studies; for those studies for which we do not have
an in-house translator available, we will find an external transla-
tor. Differences in study selection between review authors will be
resolved by discussion until consensus can be reached, or by con-
sultation with a third party (HR). We plan to include a PRISMA
study flow diagram in the full review (Liberati 2009) to document
the screening process, as recommended in Part 2, Section 11.2.1,
of the Cochrane Handbook on Systematic Reviews of Interventions
(Higgins 2011a).
Data extraction and management
Two review authors (EB, JL) will start to independently extract the
data using standardised data extraction forms developed by the re-
view authors. If necessary, in cases of disagreement or discrepancy,
data will be reviewed by a third review author (HR). When review
authors have reached agreement on the types of information to be
extracted after they have reviewed a significant proportion of the
papers, one review author (EB) will continue to extract the data
from the remaining papers. Where possible, the following infor-
mation will be obtained for each study.
1. The number of patients eligible, the number of participants
randomly assigned, and reasons why patients were not included
in the trial.
2. The number of participants evaluated at follow-up(s) and
what the follow-up time points were.
3. Participant demographics, including age, sex, diagnosis,
ICD-10 code and type of healthcare setting (hospital/hospice/
home/residential school).
4. Trial design features on masking, whether parallel group or
cross-over, features of randomisation, and sample size calculation.
5. Any necessary additional data on trial design and outcomes
to allow completion of The Cochrane Collaboration’s tool for
assessing risk of bias.
6. Comparison interventions, including duration and mode.
7. Outcome data on pain reduction at all time points,
including how outcome was measured, and mean or categorical
scores of the main outcome and other outcomes.
8. Adverse effects.
9. Comment on the success of blinding (of researchers and
participants) given the possibility of side effects unblinding
participants.
10. Drop-out rates and reasons why.
11. Concurrent use of other drugs, including analgesics, and
exclusions.
12. Quality of life of CYP and family and how this was
measured.
13. Other behavioural and psycho/social measures and the
scales used to measure them.
In cases where information is lacking, we will attempt to make
contact with trial authors or trial sponsors.
Assessment of risk of bias in included studies
We will assess and report on the risk of bias of included RCTs
using The Cochrane Collaboration’s tool for assessing risk of bias
(Higgins 2011a). This recommends explicit reporting of the fol-
lowing quality elements for RCTs: sequence generation; allocation
concealment; blinding; completeness of outcome data; and selec-
tive outcome reporting. For each quality domain, we will assess
whether the risk of bias was low (if the study matched the criteria),
high (if the study did not match the criteria) or unclear (if under-
reporting was noted). We will define trials as having an overall
low risk of bias if they score a low risk of bias on four of the five
domains in the risk of bias table. We will label a trial as having an
unclear risk of bias if the trial provided too few details to allow a
judgement of ’high’ or ’low’ risk of bias. One review author (EB)
will assess the risk of bias of included studies; one review author
(JL or HR) will check a significant proportion of papers, and dis-
agreements will be resolved by discussion. Where needed, we will
contact study authors to ask for additional information. We will
incorporate the results of the risk of bias assessment into the review
through systematic narrative description and commentary about
each item, leading to an overall assessment of the risk of bias of
included studies and a judgement about the internal validity of
the results of the review.
Measures of treatment effect
The null hypothesis to be tested is that, for the primary out-
comes examined, the pharmacological interventions have no ef-
fect compared with placebo/other interventions. For dichotomous
outcomes, we will calculate the risk ratio with 95% confidence
interval (CI), and for continuous data, we will estimate the mean
difference with 95% CI. Our reporting of these data is reliant on
presentation by study authors of relevant data to allow us to cal-
culate these statistics. To estimate the statistical significance of the
results, we will calculate the 95% CI for each item.
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Unit of analysis issues
In the event that we identify a trial using a cluster design (in which
participants were randomly assigned at group level), wewill use the
intracluster correlation coefficient (ICC) to estimate the effective
sample size. If cross-over trials are to be included in ameta-analysis,
statistical advice will be sought.
Dealing with missing data
If doubts arise about missing data (participant drop-outs, etc.),
we will contact the study authors to obtain further information.
Whenwe are unable to obtain data, we will state it.When dichoto-
mous data are missing and it has been possible to do an analysis,
we will undertake a ‘Sensitivity to missing data’ analysis. We will
address the potential impact of missing data on our findings in the
’Discussion’ section of the review.
Assessment of heterogeneity
If a meta-analysis is conducted, we will use the Chi2 test and
the I2 statistic to evaluate heterogeneity between trials (Higgins
2011b). A Chi2 test P value of less than 0.10 or an I2 value equal
to or greater than 50% will be considered indicative of substantial
heterogeneity.
Assessment of reporting biases
If a sufficient number of studies are identified and a meta-analysis
is possible, we plan to assess publication bias by using funnel plots.
However, funnel plots can be used only when a sufficient number
of studies are included in the review, as use of funnel plots with
insufficient numbers may lead the reader to the wrong conclusion
that an asymmetrical funnel plot is caused by publication bias, or
vice versa.
Data synthesis
For this review, we will first categorise the studies according to
whether they consider nociceptive pain, neuropathic pain or both.
We will then group identified evidence by the different pharmaco-
logical interventions used (i.e. non-opioids, opioids, local anaes-
thetics and adjuvants). We will consider how they are used to treat
the different types of pain, as well as the types of pain experienced
by which condition, as categorised by the ICD-10 classification. If
necessary, we will group and analyse results according to diagnosis
and extent of pain, if this proves to be a more meaningful strategy.
If there are sufficient trials by class of treatment we will combine
statistically the data across trials. This will only be undertaken if
the trials are sufficiently similar in measurement and population
and are of sufficient quality. A fixed-effect (FE) model will be used
in the first instance. If no substantial heterogeneity was noted, a
random-effects (RE) model will be used to check the robustness of
the FE model. If substantial statistical heterogeneity was observed,
the RE model will be used a priori.
Subgroup analysis and investigation of heterogeneity
If a sufficient number of trials are combined in a meta-analysis and
heterogeneity is identified between trials, subgroup analysis of the
different diagnoses (according to ICD-10 code classification) will
be undertaken.
Sensitivity analysis
We will use the GRADE system (Schunemann 2008) to assess
the quality of the evidence associated with specific outcomes (e.g.
pain reduction, quality of life improvement, adverse effects) and
will construct a ‘Summary of findings’ table using the GRADE
software. Through this approach, the body of evidence will be as-
sessed as ‘high’, ‘moderate’, ‘low’, or ‘very low’; this assessment will
give the reader confidence that an estimate of effect or association
reflects the item that is being assessed.
A C K N OW L E D G E M E N T S
None.
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A P P E N D I C E S
Appendix 1. Medline search strategy
1 exp Pain/
2 Pain Management/
3 (pain* or headache* or migraine* or neuralgia or neuropathic).mp.
4 or/1-3
5 exp Analgesics/
6 Anesthesia, Local/
7 exp Anticonvulsants/
8 exp Antidepressive Agents/
9 exp Anti-Inflammatory Agents, Non-Steroidal/
10 exp Muscle Relaxants, Central/
11 exp Parasympatholytics/
12 exp Serotonin Uptake Inhibitors/
13 exp Steroids/
14 (acetaminophen or “acetylsalicylic acid” or “alendronic acid” or alfentanil or amitriptyline or aspirin or baclofen or benzocaine or
bupivacaine or buprenorphine or butorphanol or carbamazepine or chloroprocaine or “choline magnesium trisalicylate” or clonazepam
or clonidine or codeine or dexamethasone or dexmetetomidine or dextroamphetamine or dextropropoxyphene or diamorphine or
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diazepam or diclofenac or dihydrocodeine or domperidone or fentanyl or fluoxetine or gabapentin or hydrocodone or hydromorphone
or “hyoscine hydrobromide” or ibuprofen or ketamine or ketoprofen or ketorolac or “levo bupivacaine” or lidocaine or loperamide
or lorazepam or mefenamic acid or meperidine or methadone or methylphenidate or midazolam or morphine or naproxen or nitrous
oxide or nortriptyline or oxycodone or pamidronate or paracetamol or paroxetine or pentazocine or pethidine or phenobarbital or
“phenytoin” or piroxicam or pregabalin or propoxyphene or “risedronate sodium” or “sodium clodronate” or tetracaine or tramadol or
“valproic acid”).mp.
15 exp Infant/
16 exp Child/
17 Adolescent/
18 (neonate* or newborn or infant* or child* or adolescen* or paediatric* or pediatric* or baby or babies or toddler* or teen* or
juvenile* or boy* or girl*).mp.
19 or/15-18
20 or/5-14
21 4 and 19 and 20
key:
mp = title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol All
Develop a search strategy All
Search for studies (usually 2 review authors) EB/JL (HR)
Obtain copies of studies EB
Select which studies to include (2 + 1 arbiter) All
Extract data from studies (2 review authors) EB/JL (HR)
Enter data into RevMan EB
Carry out the analysis EB
Interpret the analysis All
Draft the final write-up of the review EB
Update the review EB/LJ/MB-L
Serve as content expert RH/JL/RM
Take responsibility for grammar and language LJ
Serve as methodologist BC/VV
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(Continued)
Serve as statistician VV
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